Nanobiotix Unveils Phase 1 Results at European Lung Cancer Congress

Nanobiotix announced the presentation of data from two Phase 1 studies of JNJ-1900 (NBTXR3) at the European Lung Cancer Congress. The first study, led by Dr. Saumil Gandhi, evaluates the safety and efficacy of JNJ-1900 in patients with re-irradiation in locoregionally relapsed non-small cell lung cancer (NSCLC). The results include progression-free survival data.

The second study, presented by Dr. Colette Shen, examines the safety and feasibility of injecting JNJ-1900 with nivolumab or pembrolizumab to treat lung metastases from NSCLC or other solid tumors. Nanobiotix, a pioneer in the use of nanoparticles, continues to explore innovative cancer therapies.